Peptide chelators that predominately form a single stereoisomeric species upon coordination to a metal center
CA 2316392 A1 · Owner: Resolution Pharmaceuticals Inc. · Inventors: Pollak, Alfred; Fauconnier, Theresa; Wong, Ernest
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The labeling of biologically important molecules via a bifunctional chelator can result in the formation of isomers or multiple species which can have , significant impact on the biological properties of the radiopharmaceutical. For receptor-based radiopharmaceuticals the target uptake is largely , dependent on the receptor binding affinity of the targeting molecule and the blood clearance of the labeled molecule which is determined by the physical , properties of both the targeting molecule and the metal chelate. Hence the , presence of isomers for the metal chelate can have significant impact on the radiopharmaceutical. Therefore, in the development of a radiopharmaceutical or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 23, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.